After infusion, CAR T cells leave the blood and travel to sites of tumor, where they identify and kill tumor cells. This can trigger extensive proliferation of CAR T cells and the release of tumor ...

We previously reported the in vivo expansion and robust antileukemic effects of CTL019 (formerly CART19) cells in three patients with CLL. 7,8 CTL019 is a chimeric antigen receptor that includes a ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

This is best exemplified by chimeric antigen receptor (CAR) T-cells. Since first being tested in a patient nearly 15 years ago, six CAR T-cell products have been approved by the US Food and Drug ...

Adoptive T cell therapy using Chimeric Antigen Receptor T cells (CAR T) has made significant advances in the treatment of hematologic malignancies and solid tumors. However, a key challenge remains ...

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...

Jensen et al 17 showed that outcomes of 15 CD19- or CD20-specific chimeric antigen receptor T-cell (CAR-T) infusions in 4 patients were limited by short persistence of 1-7 days, attributed to ...

A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...

Models B to D will be open for both academic and industry license holders. CAR, chimeric antigen receptor. The figure was created with BioRender.com. To guarantee patient access eventually, novel ...